Back to Search Start Over

THU-053-Usefulness of lactate-free Asian Pacific Association for The Study of Liver acute-on-chronic liver failure research consortium ACLF score for predicting short-term mortality in patient with alcoholic liver disease

Authors :
Do Seon Song
Tae Yeob Kim
Hee Yeon Kim
Eileen L Yoon
Dong Joon Kim
Ji-Dong Jia
Ashok Choudhury
Mamun Al-Mahtab
Harshad Devarbhavi
Zhongping Duan
Yu Chen
CE Eapen
Ashish Goel
Qin Ning
Ke Ma
Yogesh Chawla
Radha Krishan Dhiman
Ajay Duseja
Sunil Taneja
Saeed Sadiq Hamid
Amna Subhan
Wasim Jafri
Soek-Siam Tan
Hasmik Ghazinian
Deepak Amarapurkar
Sombat Treeprasertsuk
Guan Huei Lee
Seng Gee Lim
Jinhua Hu Hu
Laurentius A. Lesmana
Rinaldi Lesmana
Akash Shukla
Samir Shah
Chetan Kalal
Manoj Sahoo
Zaigham Abbas
Joyes s
Gian Carpio
Md. Fazal Karim
George Lau
Nagaraja Rao Padaki
Diana Payawal
A. Kadir Dokmeci
Man-Fung Yuen
V GM
Osamu Yokosuka
Ananta Shrestha
Priyanka Jain
Irene Paulson
Shiv Kumar Sarin
Source :
Journal of Hepatology. 70:e184
Publication Year :
2019
Publisher :
Elsevier BV, 2019.

Abstract

Aims: Asian Pacific Association for the Study of Liver (APASL) acute-on-chronic liver failure (ACLF) Research Consortium (AARC) proposed new prognostic scoring system of ACLF in cluding lactate. However, lactate is not routinely checked in clinical practice of patient with ACLF in Korea. Therefore, we aimed to investigate the predictive accuracy of lactate-free AARC-ACLF score for predicting short-term mortality in patients with alcoholic liver disease. Methods: A total of 749 ALD patients who had liver failure (bilirubin≥5mg/dL and INR≥1.5) in AARC database were in vestigated. Diagnostic performances for short-term mortality were compared according to the area under receiver operating characteristic (AUROC) curve. Predictive accuracy of lactate-free AARC-ACLF score were compared with other prognostic scores in 143 ALD patients with liver failure and 60 ALD patients with ACLF according to AARC definition in Korean ACLF cohort. Results: Among 749 patients, 30-day and 90-day mortality were 40.3% and 51.5%. There were no significant differences in AUROC for predicting 30-day and 90-day mortality between AARC-ACLF score and lactate-free AARC-ACLF score (30-day mortality: 0.752 vs. 0.751, P=0.918, 90-day mortality: 0.728 vs. 0.736, P=0.346). In Korean ACLF cohort, the AUROCs of lactate-free AARC-ACLF score for predicting 28-day and 90- day mortality were 0.861 and 0.846 in ALD with liver failure, and 0.884 and 0.874 in ALD patients with ACLF according to AARC definition, respectively. In Korean ALD patients with liver failure and ACLF according to AARC definition, diagnostic per formance of lactate-free AARC-ACLF score for predicting 28- day and 90-day mortality was comparable to those of Model for End-stage Liver Disease (MELD), MELD-Na, Chronic Liver Failure-Sequential Organ Failure Assessment score. Conclusions: Lactate-free AARC-ACLF score is as excellent as AARC-ACLF score in predicting short-term mortality in ALD patients with liver failure of AARC database and Korean ACLF cohort.

Details

ISSN :
01688278
Volume :
70
Database :
OpenAIRE
Journal :
Journal of Hepatology
Accession number :
edsair.doi...........264c0ea02d7651e93803aaead0a64960
Full Text :
https://doi.org/10.1016/s0618-8278(19)30336-6